AstraZeneca's British Investment on Pause

AstraZeneca, the London-listed pharmaceutical company, has put its planned £650 million investment in UK vaccine research and development on hold. The pause is due to ongoing discussions with the UK government regarding potential incentives. No new updates were shared after the third-quarter results briefing.

AstraZeneca, the London-listed pharmaceutical giant, has announced a hold on its ambitious £650 million investment plan in the UK. The decision comes as the company waits for further negotiations with the British government over potential incentives for vaccine research and development.

During a recent media briefing, AstraZeneca's Chief Financial Officer, Aradhana Sarin, stated that discussions with the government are ongoing, and the company has no new information to release at this time. This statement followed the announcement of AstraZeneca's third-quarter financial results.

The proposed investment was initially revealed in March, aiming to bolster the UK's position in the global vaccine development arena. However, with negotiations still in progress, the future of AstraZeneca's investment remains uncertain.

(With inputs from agencies.)